Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Dynamicure Biotechnology LLC currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This specific workload is concentrated under 1 distinct examiner and 1 distinct art unit. The focus of current prosecution activity rests entirely with examiner HALVORSON, MARK, who is responsible for the 1 busiest examiner pending office action.
For a practitioner, this centralized portfolio structure means that prosecution outcomes are currently dependent on the assigned personnel at the USPTO. With 1 distinct examiner involved, the applicant lacks the diversity of examiner perspectives that larger portfolios often encounter. The presence of 1 distinct art unit suggests a narrow technological focus for the pending matters within this sector.
The active workload assigned to HALVORSON, MARK represents the total current engagement with the office. Monitoring the specific tendencies and past allowance rates of this individual is critical, as there are no other pending actions to balance potential difficulties. This arrangement defines the current landscape for Dynamicure Biotechnology LLC.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HALVORSON, MARK | 1 | 47.9% | +20.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280458 | ANTI-VISTA CONSTRUCTS AND USES THEREOF | HALVORSON, MARK | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18280458 | ANTI-VISTA CONSTRUCTS AND USES THEREOF | HALVORSON, MARK | 1646 | §112 | Non-Final OA | — | Pending | Sep 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDynamicure Biotechnology LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mark Halvorson has the most, with 1 of Dynamicure Biotechnology LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
